本帖最后由 老马 于 2012-1-13 21:20 编辑 7 w# @* o) r7 M V2 P5 C1 [
0 e& _ x- [$ l7 f0 i0 O: u4 {
爱必妥和阿瓦斯丁的比较$ v: v: r5 v( J
$ e+ ?; z0 O6 o/ @; F* U# V
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
! ]' P4 n8 Y$ X; j% Q7 a
$ s8 y9 h) W* h! q
) }3 u* a7 L5 i" u, s( S0 Q/ Shttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# m d5 ^8 {5 `: c/ I/ v==================================================
8 T% y$ }) x7 j$ u; n) S4 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, |/ Y) u3 s' N$ g5 CPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 ` F; j3 {- ~/ VResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
+ A+ Y; C3 p4 x6 c
|